Press Releases
Date Title and Summary View
Oct 20, 2016 SAN DIEGO, Oct. 20, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced it will report third quarter 2016 financial results on Thursday, November 3, 2016 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:...
Oct 6, 2016 SAN DIEGO, Oct. 06, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced Alvin Shih, M.D., will be stepping down from his position as executive vice president and head of research and development to become chief executive officer of a start-up biotechnology company. Dr. Shih will remain in his current role until October 31, 2016...
Sep 30, 2016 SAN DIEGO, Sept. 30, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced that its Board of Directors has granted an inducement award pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules to Julio Gagne in connection with his employment as vice president, Program Management. Mr. Gagne's employment with Retrophin began tod...
Sep 14, 2016 SAN DIEGO, Sept. 14, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced that Alvin Shih, M.D., executive vice president and head of research & development, will present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series in New York City on Wednesday, September 28, 2016 at 11:05 a.m. ET. A live webcas...
Sep 7, 2016 Combined sparsentan treatment group experienced 44.8 percent reduction of proteinuria, more than double the reduction of irbesartan; achieves statistical significance in primary efficacy endpoint Preliminary safety findings show sparsentan was generally safe and well-tolerated Conference call scheduled for today at 8:30 a.m. ET SAN DIEGO, S...
Aug 15, 2016 SAN DIEGO, Aug. 15, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced Neil McFarlane has been appointed chief operating officer. In this newly created position, Mr. McFarlane will help guide the Company's daily operations with principal responsibility for commercial operations, business development, patient services, and prog...
Aug 4, 2016 Second quarter revenues increased 38 percent year-over-year Sparsentan top-line data expected in third quarter of 2016 RE-024 efficacy trial expected to initiate in second half of 2016 SAN DIEGO, Aug. 04, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today reported its second quarter 2016 financial results. Net product sales for...
Jul 21, 2016 SAN DIEGO, July 21, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced it will report second quarter 2016 financial results on Thursday, August 4, 2016 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:3...
Jul 19, 2016 SAN DIEGO, July 19, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced the appointment of Roy D. Baynes, M.D., Ph.D., to its Board of Directors, effective immediately. Dr. Baynes currently serves as senior vice president of Global Clinical Development at Merck Research Laboratories. "I am pleased to welcome Dr. Baynes to ...
Jun 23, 2016 SAN DIEGO, June 23, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced new data from physician-initiated treatment with RE-024, the company's novel investigational replacement therapy for pantothenate kinase-associated neurodegeneration (PKAN), a rare and life-threatening genetic condition characterized by a host of progressiv...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase